Pathophysiology of hemophilic arthropathy and potential targets for therapyAstrid E. Pulles, Lize F. D. van Vulpen, S.C. Mastbergen et al.|Pharmacological Research|2016Cited by 143
IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)Dima El‐Sharkawi, Nirav N. Shah, David Lewis et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
POSTER: IBCL-675 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM)Dima El‐Sharkawi, Nirav N. Shah, Kim Linton et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1